CompletedPhase 2NCT00433550
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
Studying Rare tumor of small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Robert McWilliams, MDMayo Clinic
- Intervention
- capecitabine(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2016
Study locations (30)
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
- Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States
- Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States
- CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
- John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States
- Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
- John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States
- Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
- Mercy Medical Center - Sioux City, Sioux City, Iowa, United States
- St. Luke's Regional Medical Center, Sioux City, Iowa, United States
- Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States
- Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · Pfizer · Sanofi
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00433550 on ClinicalTrials.gov